Literature DB >> 4208459

The use of immunoadsorbent columns for the isolation of antibodies specific for antigens associated with human bronchogenic carcinoma.

R D Watson, A G Smith, J G Levy.   

Abstract

An immunoadsorbent technique is described whereby tumour-specific antibodies may be isolated. Extracts from normal human lung tissue were pooled and bound to cyanogen bromide activated Sepharose 4B. Antisera raised in rabbits to a variety of extracts from human bronchogenic carcinoma were passed through these immunoadsorbent columns to yield antisera specific for tumour-associated antigens as demonstrated by immunodiffusion and immunoelectrophoresis.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4208459      PMCID: PMC2009101          DOI: 10.1038/bjc.1974.57

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  In vitro study of cellular immunity against autochthonous human cancer.

Authors:  A Segall; O Weiler; J Genin; J Lacour; F Lacour
Journal:  Int J Cancer       Date:  1972-03-15       Impact factor: 7.396

2.  Immunochemical studies on human lung cancer antigens soluble in 50 per cent saturated ammonium sulfate.

Authors:  A Yachi; Y Matsuura; C M Carpenter; L Hyde
Journal:  J Natl Cancer Inst       Date:  1968-04       Impact factor: 13.506

3.  Antigen solubilized from human solid tumours: lymphocyte stimulation and cutaneous delayed hypersensitivity.

Authors:  G M Mavligit; U Ambus; J U Gutterman; E M Hersh; C M McBride
Journal:  Nat New Biol       Date:  1973-06-06

4.  Immunologic studies of human serous cystadenocarcinoma of ovary. Demonstration of tumor-associated antigens.

Authors:  M Bhattacharya; J J Barlow
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

5.  Chemical coupling of proteins to agarose.

Authors:  J Porath; R Axen; S Ernback
Journal:  Nature       Date:  1967-09-30       Impact factor: 49.962

6.  Antigen solubilized from human leukemia: lymphocyte stimulation.

Authors:  J U Gutterman; G Mavligit; K B McCredie; G P Bodey; E J Freireich; E M Hersh
Journal:  Science       Date:  1972-09-22       Impact factor: 47.728

7.  Salt extraction of soluble HL-A antigens.

Authors:  R A Reisfeld; M A Pellegrino; B D Kahan
Journal:  Science       Date:  1971-06-11       Impact factor: 47.728

8.  Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens.

Authors:  I Hellström; K E Hellström; C A Evans; G H Heppner; G E Pierce; J P Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1969-02       Impact factor: 11.205

9.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

  9 in total
  6 in total

1.  Immunopotentiation with levamisole in resectable bronchogenic carcinoma: a double-blind controlled trial; Study Group for Bronchogenic Carcinoma.

Authors: 
Journal:  Br Med J       Date:  1975-08-23

2.  Cancer and the immunity system--1977.

Authors:  R A Good
Journal:  West J Med       Date:  1977-02

3.  Immunological responsiveness and adjunct immunotherapy in lung cancer.

Authors:  M Fukushima; S Machida; H Kakuta; T Nishikawa; A Kikuchi; K Takashima; T Ishioka; Y Ishikawa
Journal:  Jpn J Surg       Date:  1978-12

4.  Extraction and preliminary characterization of a human bronchogenic carcinoma antigen.

Authors:  M J Frost; G T Rogers; K D Bagshawe
Journal:  Br J Cancer       Date:  1975-04       Impact factor: 7.640

5.  The detection by immunodiffusion of tumour associated antigenic components in extracts of human bronchongenic carcinoma.

Authors:  R D Watson; A G Smith; J G Levy
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

6.  A human tumour-associated membrane antigen from squamous-cell carcinoma of the lung.

Authors:  R W Veltri; P E Maxim; J M Boehlecke
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.